Martin I Freed
Overview
Explore the profile of Martin I Freed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lipp M, Batycky R, Moore J, Leinonen M, Freed M
Sci Transl Med
. 2016 Oct;
8(360):360ra136.
PMID: 27733560
Inhaled drugs offer advantages, such as rapid onset of action, but require formulations and delivery systems that reproducibly and conveniently administer the drug. CVT-301 is a powder formulation of levodopa...
2.
Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations
Hampson N, Kieburtz K, LeWitt P, Leinonen M, Freed M
Int J Neurosci
. 2016 Jun;
127(3):276-284.
PMID: 27345931
Background: Spirometry patterns suggesting restrictive and obstructive pulmonary dysfunction have been reported in Parkinson's disease (PD). However, the patterns' precise relation to PD pathophysiology remains unclear. Purpose/Aim. To assess ON-...
3.
LeWitt P, Hauser R, Grosset D, Stocchi F, Saint-Hilaire M, Ellenbogen A, et al.
Mov Disord
. 2016 Apr;
31(9):1356-65.
PMID: 27090868
Background: Although levodopa is the most effective oral PD therapy, many patients experience motor fluctuations, including sudden loss of dose effect and delayed benefit. CVT-301 is a levodopa inhalation powder...
4.
Evans E, Tester R, Aslanian S, Karp R, Sheets M, Labenski M, et al.
J Pharmacol Exp Ther
. 2013 May;
346(2):219-28.
PMID: 23709115
Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies. Bruton's tyrosine kinase (Btk) plays a crucial role in...
5.
Bakris G, Ruilope L, McMorn S, Weston W, Heise M, Freed M, et al.
J Hypertens
. 2006 Sep;
24(10):2047-55.
PMID: 16957566
Objective: To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control. Methods:...
6.
Kahn S, Zinman B, Haffner S, ONeill M, Kravitz B, Yu D, et al.
Diabetes
. 2006 Jul;
55(8):2357-64.
PMID: 16873701
The inflammatory factor C-reactive protein (CRP) and the fibrinolytic variables fibrinogen and plasminogen activator-1 (PAI-1) are associated with long-term cardiovascular morbidity. To determine the contribution of body adiposity (BMI), insulin...
7.
Ryan C, Freed M, Rood J, Cobitz A, Waterhouse B, Strachan M
Diabetes Care
. 2006 Jan;
29(2):345-51.
PMID: 16443885
Objective: The goals of this study were to determine whether improvements in metabolic control can ameliorate the cognitive dysfunction associated with type 2 diabetes and evaluate the possibility that such...
8.
Herman W, Dirani R, Horblyuk R, ONeill M, Kravitz B, Heise M, et al.
Am J Manag Care
. 2005 Apr;
11(4):273-8.
PMID: 15839187
Objective: To assess and compare healthcare utilization and costs over a 2-year period in older patients (> or = 60 years) with type 2 diabetes receiving combination therapy with rosiglitazone...
9.
Smith S, Porter L, Biswas N, Freed M
J Clin Endocrinol Metab
. 2004 Dec;
89(12):6048-53.
PMID: 15579757
An elevation in the ratio of proinsulin (PI) to immunoreactive insulin (IRI) is inversely related to beta-cell function in type 2 diabetes, and increased PI is an independent risk factor...
10.
Zinman B, Kahn S, Haffner S, ONeill M, Heise M, Freed M
Diabetes
. 2004 Nov;
53(12):3193-200.
PMID: 15561950
A number of patients with type 2 diabetes are GAD antibody positive. A Diabetes Outcome Progression Trial (ADOPT) is a randomized, double-blind clinical trial in recently diagnosed drug-naive patients with...